(Q35826388)

10 August 2017

1 reference

title

Progress in DNA-based heterologous prime-boost immunization strategies for malaria (English)

1 reference

10 August 2017

0 references

0 references

2

Adrian V S Hill

1 reference

10 August 2017

Anne C Moore

1

1 reference

10 August 2017

publication date

1 June 2004

1 reference

10 August 2017

published in

Immunological Reviews

1 reference

10 August 2017

volume

199

1 reference

10 August 2017

page(s)

126-143

1 reference

Malaria. A renewed assault on an old and deadly foe.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

The immunology of malaria infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Common west African HLA antigens are associated with protection from severe malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Immune effector mechanisms in malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

CD4+ cytolytic T cell clone confers protection against murine malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Pathways and strategies for developing a malaria blood-stage vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Nucleic acid immunization: concepts and techniques associated with third generation vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

DNA vaccines: immunology, application, and optimization*

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

HIV-1 DNA vaccines and chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Vaccinia virus expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

NYVAC: a highly attenuated strain of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Development of a preventive vaccine for Ebola virus infection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

A protein particle vaccine containing multiple malaria epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Clinical responses to undiluted and diluted smallpox vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Immunity to non-cerebral severe malaria is acquired after one or two infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Immune responses to adenovirus and adeno-associated virus in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Replication-defective vector based on a chimpanzee adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Poxviral mimicry of complement and chemokine system components: what's the end game?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00138.X

10.1111/J.0105-2896.2004.00138.X

21 January 2018

Identifiers

DOI

1 reference

release_2lwuwaopvbbkro4nckj5zcpqui

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2lwuwaopvbbkro4nckj5zcpqui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference